Discussion about this post

User's avatar
Darcy Rock's avatar

All of this has buoyed my spirit immensely to day.

Neural Foundry's avatar

Fascinating roundup! Your coverage of DeepMind's automated research lab and the R21 malaria vaccine rollout highlights how strategic investments in biomedical research can accelerate breakthroughs. I'm particularly interested in how AI-driven discovery platforms could benefit rare disease research, where traditional pharmaceutical development often fails due to small patient populations and limited profit incentives. The budget cuts to NSF and NIH you mentioned are especially concerning for rare disease patients - these conditions affect 30 million Americans but often get deprioritized when science funding shrinks. When Congress fights to preserve basic research funding, they're also protecting the pipeline of treatments for conditions that affect 1 in 10 people but capture far less than 10% of research attention. The automated materials science approach could be revolutionary for orphan drug development if applied to biologics and small molecules.

5 more comments...

No posts

Ready for more?